Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | GGH | Q92820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516528 | 1.00 | KMT2A (0.47) | KMT2AALOX15BLMPMP22FOLH1 | |
| Dimethylamine SCHEMBL27971627 | 0.96 | KMT2A (0.44) | KMT2AALOX15BLMPMP22FOLH1 | |
| Dimethylamine SCHEMBL27971599 | 0.94 | KMT2A (0.42) | KMT2AALOX15BLMPMP22FOLH1 | |
| SCHEMBL2242496 | 0.85 | NOD1 (0.46) | KMT2AALOX15BLMPMP22FOLH1 | |
| SCHEMBL22384097 | 0.85 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLANOD1GGH | |
| SCHEMBL5023601 | 0.85 | NOD1 (0.46) | KMT2AALOX15BLMPMP22FOLH1 | |
| Theanine SCHEMBL23068689 | 0.84 | ALOX15 (0.54) | KMT2AALOX15BLMPMP22FOLH1 | |
| SCHEMBL16281272 | 0.84 | KMT2A (0.38) | KMT2AALOX15BLMPMP22FOLH1 | |
| SCHEMBL73336 | 0.83 | FOLH1 (0.63) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL911011 | 0.83 | FOLH1 (0.63) | FOLH1NAALAD2RIMKLAGGH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304557-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | MarvelBiome, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| WO-2022192755-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | MarvelBiome, Inc. (US) | 2022-09-15 | — | — | WO | claimed |
| CN-109073551-A | Application of ultrashort peptide as exogenous second harmonic probe in biological imaging | 新加坡科技研究局 | 2018-12-21 | — | — | CN | claimed |
| CN-107406487-A | Self-assembling ultrashort aliphatic depsipeptides for biomedical applications | 新加坡科技研究局 | 2017-11-28 | — | — | CN | claimed |
| US-20170299597-A1 | COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER | KEIO UNIVERSITY (JP) | 2017-10-19 | — | — | US | claimed |
| US-20150038522-A1 | COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER | KEIO UNIVERSITY (JP) | 2015-02-05 | — | — | US | claimed |
| EP-2818870-A1 | COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER | Keio University (JP) | 2014-12-31 | — | — | EP | claimed |
| CN-104169721-A | Combined sensitivity-determining marker for anticancer agent | UNIV KEIO | 2014-11-26 | — | — | CN | claimed |
| EP-0213996-B1 | RAMIFIED POLYMERS BASED ON LIPOPEPTIDES FORMING THERMOTROPIC AND LYOTROPIC LIQUID CRYSTALS, THEIR USE AND CORRESPONDING MONOMERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1989-09-06 | — | — | EP | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20240182532-A1 | MICROPEPTIDES AND USES THEREOF | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-06-06 | — | — | US | disclosed |
| US-20240066075-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | MarvelBiome, Inc. | 2024-02-29 | — | — | US | disclosed |
| EP-4304557-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | MarvelBiome, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11858972-B2 | Micropeptides and uses thereof | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-01-02 | — | — | US | disclosed |
| EP-0571198-B1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1997-03-19 | — | — | EP | disclosed |
| CN-1136764-A | Flavouring compositions and its preparing method | FIRMENICH & CIE (CH) | 1996-11-27 | — | — | CN | disclosed |
| US-5559092-A | HAIR GROWTH, GLUTAMINE DIPEPTIDE | CHESEBROUGH-POND'S USA CO. DIVISION OF CONOPCO, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0731648-A1 | FLAVOURING COMPOSITIONS AND METHOD | FIRMENICH SA (CH) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996010927-A1 | FLAVOURING COMPOSITIONS AND METHOD | FIRMENICH S.A. (CH) | 1996-04-18 | — | — | WO | disclosed |
| EP-0571198-A1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | KMT2A 2945/4885ALOX15 2075/4885BLM 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.